San Juan, Puerto Rico--(Newsfile Corp. - February 11, 2025) - Hemostemix PR Inc. proudly congratulates Luis Muñoz Marín International Airport (SJU) on achieving the prestigious CEIV Pharma Certification from the International Air Transport Association (IATA). This milestone reinforces Puerto Rico's status as a global leader in the logistics of biologics and pharmaceutical products.
The CEIV Pharma Certification ensures the highest standards in the handling, storage, and transportation of biologics and pharmaceutical products, meeting rigorous international criteria for quality and safety. With this certification, SJU joins an elite group of major global hubs such as Miami and Amsterdam, further positioning Puerto Rico as a strategic nexus in the global biologics and pharmaceutical supply chain.
"The achievement of CEIV Pharma Certification by Luis Muñoz Marín International Airport is a testament to Puerto Rico's commitment to excellence in biologics and pharmaceutical logistics," said Thomas Smeenk, President & CEO, Hemostemix PR Inc. "This certification provides Hemostemix PR Inc. with access to a world-leading, certified biologics logistics hub, enabling the efficient delivery of ACP-01 therapies to patients across the globe," Smeenk said.
This strategic advancement not only enhances Puerto Rico's logistics capabilities but also supports Hemostemix PR Inc.'s mission to improve patient outcomes worldwide through cutting-edge regenerative therapies. The robust, certified infrastructure at SJU ensures that sensitive biologics like ACP-01 are transported with the highest levels of care and compliance, meeting the stringent demands of Hemostemix.
Hemostemix PR Inc. is leveraging this state-of-the-art logistics hub to expand its global reach to deliver its life-changing ACP-01 treatment to those in need.
About Hemostemix PR Inc. Hemostemix PR Inc., a wholly owned subsidiary of Hemostemix Inc., (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is focused on the commercialization of ACP-01. Demonstrated to improve the recipients' quality of life and longevity, ACP-01 is Your Fountain of Youth (tm). Patients suffering from angina, ischemic and dilated cardiomyopathy, congestive heart failure, vascular dementia, peripheral arterial disease and chronic limb threatening ischemia, who were treated with ACP-01 experienced a safe infusion of their own stem cells, and a clinically relevant and statistically significant improvement in heart function, circulation, exercise capacity, wound healing, cessation of pain and reduced limb amputation rates. Published in nine peer reviewed journals, seven clinical trials of 318 subjects (1 phase II, 5 phase I's, 1 retrospective study) demonstrate ACP-01 is safe, clinical relevant, and statistically significant. Saving a limb from amputation is saving a life.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to sales of its lead product ACP-01, the commercialization of ACP-01 via the sale of compassionate treatments under Special Access Program. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemis may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
